Open Actively Recruiting

Nafamostat Efficacy in Phase 3 Registrational CRRT Study

About

Brief Summary

A prospective, randomized, placebo-controlled clinical study to investigate the safety and efficacy of Niyad (nafamostat mesylate) for anticoagulation of extracorporeal blood circulating through a dialysis filter in patients undergoing CRRT who cannot tolerate heparin or are at higher risk for bleeding.

Primary Purpose
The main objective of the intervention(s) being evaluated by the clinical trial. Learn more
Treatment
Study Type
The nature of the investigation or investigational use for which clinical study information is being submitted. Learn more
Interventional
Phase
Phase 3

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
80 Years

Inclusion Criteria:

  • Patients requiring CRRT or undergoing CRRT initiated within the prior 48 hours
  • Patients who cannot tolerate heparin or are at high risk of bleeding

Exclusion Criteria:

  • Patients weighing less than 50 kg
  • Patients receiving systemic anticoagulation
  • Patients with active bleeding

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Pre-Screen Now
Call Me Back
855-731-6040
Study Stats
Protocol No.
23-5258
Category
Genitourinary Disorders
Principal Investigator
Contact
  • Jennifer Scovotti
Location
  • UCLA Westwood
For Providers
NCT No.
NCT06150742
For detailed technical eligibility, visit ClinicalTrials.gov.